Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

Rhea-AI Summary

CSL and Arcturus Therapeutics announced that Nature Communications published results from an integrated phase 1/2/3a/3b study on ARCT-154, a self-amplifying mRNA COVID-19 vaccine. The study demonstrates that two 5 μg doses of ARCT-154 were well-tolerated and provided significant protection against multiple COVID-19 strains. The vaccine showed 100% efficacy against severe COVID-19 in healthy individuals aged 18-59 and over 90% efficacy in at-risk populations. These results add to previous findings showing superior immunogenicity to Omicron BA 4/5 and longer-lasting immunity compared to conventional mRNA boosters. The vaccine's approval in Japan marks a significant milestone in the fight against COVID-19.

Positive

• Nature Communications published peer-reviewed data on ARCT-154.
• Two 5 μg doses of ARCT-154 were well-tolerated.
• ARCT-154 showed 100% efficacy against severe COVID-19 in healthy 18-59 age group.
• Efficacy was over 90% in at-risk populations.
• Approval in Japan for ARCT-154, the first sa-mRNA COVID-19 vaccine for adults.
• Demonstrated superior immunogenicity to Omicron BA 4/5 over conventional mRNA boosters.
• Longer-lasting immunity compared to traditional COVID-19 mRNA boosters.

Negative

• No specific negative financial or clinical data were mentioned in the PR.

Medical Research Analyst

The publication of the data in Nature Communications is a significant step in the validation of the self-amplifying mRNA (sa-mRNA) technology. The fact that ARCT-154 showed 100% efficacy against severe COVID-19 in healthy individuals aged 18-59 is remarkable and suggests a strong potential to impact the ongoing fight against COVID-19. Additionally, the efficacy rate of over 90% in at-risk populations is also highly promising.

This sa-mRNA vaccine differs from conventional mRNA vaccines as it amplifies itself within the body, potentially leading to stronger and longer-lasting immune responses with lower doses. In this case, the two 5 μg doses appear to provide effective and prolonged protection, which could address some of the current limitations of traditional COVID-19 vaccines like the need for frequent boosters.

These results could lead to increased interest and investment in sa-mRNA technology, not only for COVID-19 but potentially for other infectious diseases as well. For investors, the data signals potential long-term profitability and a competitive edge in the biotechnology market.

Financial Analyst

For CSL and Arcturus Therapeutics, these results could have a substantial financial impact. The efficacy and tolerability of ARCT-154, especially with such positive data published in a reputable journal, bolster the companies' reputations and market positions. The approval in Japan marks a significant milestone, as it can serve as a precedent for approvals in other major markets, potentially leading to increased sales and revenue streams.

CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) could see a positive stock reaction as the market digests these findings. Investors may view this as a strong signal of growth, especially considering the potential for expanding the vaccine's use globally. Moreover, the association with CSL, a globally respected biotech leader, provides additional credibility and market confidence.

With the ongoing interest in COVID-19 vaccines and the need for effective solutions against emerging variants, this collaboration could result in substantial market share capture and long-term growth for both companies. However, investors should also consider the competitive landscape and regulatory challenges that could impact the timeline and extent of these benefits.

Market Research Analyst

The successful results from the ARCT-154 trials place CSL and Arcturus Therapeutics at a competitive advantage within the COVID-19 vaccine market. The unique self-amplifying mRNA (sa-mRNA) technology offers a distinctive differentiation from existing mRNA vaccines, presenting a novel mechanism that could resonate well with both healthcare providers and consumers who are looking for more durable immunity with fewer doses.

The global market for COVID-19 vaccines remains robust, especially with the emergence of new variants that challenge existing vaccine efficacy. ARCT-154's demonstrated effectiveness against multiple strains, particularly against Omicron BA 4/5, positions it well to capture a significant market share. This could be especially relevant in markets that have been heavily impacted by these variants.

However, the companies need to strategically navigate regulatory approvals in other key markets such as the US and EU to fully realize this potential. Successful penetration in these regions could lead to widespread adoption, substantial sales and partnerships or licensing deals that further strengthen their market position.

• Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. 
• These results add to recently published data on ARCT-154 demonstrating superior immunogenicity to Omicron BA 4/5 compared to conventional mRNA COVID-19 vaccine booster and follow-up data demonstrating longer duration of immunity compared to traditional COVID-19 mRNA vaccine booster.

KING OF PRUSSIA, Pa. and SAN DIEGO, May 20, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT, 154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world's first approved sa-mRNA COVID-19 vaccine.

The results demonstrate that two 5 μg doses of ARCT-154, sa-mRNA vaccine, were well-tolerated, immunogenic and provided significant protection against multiple strains of COVID-19. The efficacy of ARCT-154 against severe COVID-19 was 100 percent in healthy persons aged 18-59 and more than 90 percent in persons at risk of severe consequences of the disease due to co-morbidities or older age.

"The results published in Nature Communications demonstrate the efficacy and tolerability of ARCT-154 and add to a growing body of evidence that our sa-mRNA vaccine has the potential to provide significant protection against the pervasive virus, reinforcing our promise to protect public health," said Jon Edelman, M.D., Senior Vice President, Vaccines Innovation Unit, CSL.

"We are thrilled that the results of the ARCT-154 study have been published in the highly respected journal Nature Communications," said Pad Chivukula, Ph.D., Chief Scientific Officer of Arcturus Therapeutics. "These data and the approval in Japan highlight the strength of our and CSL's commitment to delivering innovative technology that protects the public from COVID-19."

The Nature Communications article titled, "Safety and immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19; pooled phase 1, 2, 3a, and 3b randomized, controlled trials" was published online.

About the study
During the observer-blind, randomized, controlled phase 1, 2, 3a and 3b integrated study, adults ≥18 years old receive two 5 μg doses of ARCT-154 or saline placebo 28 days apart. Phase 2/3a/3b participants were stratified by age (< 60 or ≥ 60 years of age) and by risk of severe COVID-19 prior to being randomized 3:1 (phase 1/2/3a) or 1:1 (phase 3b) to vaccine or placebo groups. The primary endpoints were vaccine efficacy up to 2 months after dose 2, reactogenicity within up to 7 days of each dose, safety within up to 28 days after each dose, and immunogenicity measured 28 days after each dose From August 15 to January 12, 2023, 1,001 participants were randomized (748 ARCT-154 and 253 placebo) in the integrated phase 1/2/3a study, and 16,100 participants (8,056 ARCT-154 and 8,044 placebo) in the phase 3b study. 

In the phase 1/2/3a studies, ARCT-154 was safe and well tolerated. Most solicited adverse events were mild or moderate and resolved quickly, and rates of related or severe unsolicited adverse events were similar in the ARCT-154 and placebo groups. The phase 3b study confirmed these observations.

Four weeks after the second ARCT-154 dose in phase 3b, the neutralizing antibody seroconversion rate was 94.1% (95% CI: 92•1–95•8). There were 640 confirmed, protocol-defined COVID-19 cases, mainly of the Delta variant, that were determined to be eligible for analysis, including 43 severe cases and 10 deaths attributed to COVID-19. ARCT-154 absolute efficacy was 56.6% (95% CI: 48.7– 63.3) against any COVID-19, 95•3% (80.5–98.9) against severe COVID-19 and 86.5% (-7.4–98.3) against death due to COVID-19. Efficacy against severe COVID-19 was 100% in healthy 18-59-year-olds and 91.9% (37.9-98.9) in participants in that age group with underlying co-morbidities, which put them at risk for severe disease. In adults aged 60 years or older, efficacy was 54.3% (28.2–70.9) against COVID-19 of any severity and 94.4% (58.2–99.3) against severe COVID-19.

The study was co-funded by Vinbiocare Biotechnology Joint Stock Company in Hanoi, Vietnam, and Arcturus Therapeutics.

About sa-MRNA
mRNA vaccines help protect against infectious diseases by providing a blueprint for cells in the body to make a protein to help our immune systems recognize and fight the disease. Unlike standard mRNA vaccines, self-amplifying mRNA vaccines instruct the body to make more mRNA and protein to boost the immune response.

About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSL. For more information about CSL, visit www.CSL.com.

About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine (Kostaive®) in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

CSL Media Contacts:
Sue Thorn
Mobile: 617 799 3151
Email: sue.thorn@cslbehring.com

Australia:
Kim O'Donohue
Mobile: 0449 884 603
Email: kim.odonohue@csl.com.au

Jimmy Baker
Mobile: +61 450 909 211
Email: Jimmy.Baker@csl.com.au

Arcturus Media Contact:
Neda Safarzadeh
VP, Head of IR/PR/Marketing
Email: IR@arcturusrx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nature-communications-publishes-pivotal-data-demonstrating-efficacy-and-tolerability-of-csl-and-arcturus-therapeutics-covid-19-vaccine-302149979.html

SOURCE CSL

FAQ

What is the efficacy of ARCT-154 according to the study published in Nature Communications?

The study shows ARCT-154 has 100% efficacy against severe COVID-19 in healthy individuals aged 18-59 and over 90% efficacy in at-risk populations.

When was the ARCT-154 study published in Nature Communications?

The study was published on May 20, 2024.

What is the significance of ARCT-154's approval in Japan for CSL?

Approval in Japan marks a significant milestone as ARCT-154 is the first self-amplifying mRNA COVID-19 vaccine approved for adults.

How does ARCT-154 compare to conventional mRNA COVID-19 boosters?

ARCT-154 shows superior immunogenicity to Omicron BA 4/5 and offers longer-lasting immunity compared to conventional mRNA COVID-19 boosters.

What are the key findings of the ARCT-154 study mentioned in the PR?

Key findings include 100% efficacy against severe COVID-19 for ages 18-59, over 90% efficacy for at-risk populations, and superior immunogenicity and longer-lasting immunity compared to conventional boosters.